Replimune Group, Inc. $REPL Stake Reduced by Fcpm Iii Services B.V.

Fcpm Iii Services B.V. cut its stake in Replimune Group, Inc. (NASDAQ:REPL) by 32.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,808,368 shares of the company’s stock after selling 1,350,000 shares during the quarter. Replimune Group comprises about 3.6% of Fcpm Iii Services B.V.’s investment portfolio, making the stock its 7th biggest position. Fcpm Iii Services B.V. owned 3.40% of Replimune Group worth $27,297,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in REPL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Replimune Group by 17.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 44,352 shares of the company’s stock valued at $435,000 after purchasing an additional 6,653 shares during the period. Millennium Management LLC raised its position in Replimune Group by 2.8% in the first quarter. Millennium Management LLC now owns 1,223,236 shares of the company’s stock valued at $11,927,000 after purchasing an additional 33,574 shares during the period. Goldman Sachs Group Inc. raised its position in Replimune Group by 20.9% in the first quarter. Goldman Sachs Group Inc. now owns 690,167 shares of the company’s stock valued at $6,729,000 after purchasing an additional 119,145 shares during the period. Rhumbline Advisers grew its stake in shares of Replimune Group by 6.9% during the second quarter. Rhumbline Advisers now owns 102,005 shares of the company’s stock valued at $948,000 after acquiring an additional 6,616 shares in the last quarter. Finally, Sei Investments Co. grew its stake in shares of Replimune Group by 149.5% during the second quarter. Sei Investments Co. now owns 30,478 shares of the company’s stock valued at $283,000 after acquiring an additional 18,263 shares in the last quarter. 92.53% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Wall Street Zen upgraded Replimune Group from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 23rd. Leerink Partners restated a “market perform” rating and set a $2.00 target price (down from $11.00) on shares of Replimune Group in a research note on Monday, April 13th. Wedbush raised their target price on Replimune Group from $2.00 to $6.00 and gave the company a “neutral” rating in a research note on Monday, June 1st. Cantor Fitzgerald downgraded Replimune Group from an “overweight” rating to a “hold” rating in a research note on Monday, April 13th. Finally, Piper Sandler downgraded Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 target price for the company. in a research note on Friday, April 10th. Seven investment analysts have rated the stock with a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Reduce” and a consensus target price of $4.88.

Insider Buying and Selling

In related news, insider Christopher Sarchi sold 12,000 shares of Replimune Group stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $9.24, for a total value of $110,880.00. Following the completion of the transaction, the insider directly owned 180,962 shares in the company, valued at approximately $1,672,088.88. This trade represents a 6.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 5.20% of the company’s stock.

Replimune Group Stock Down 2.0%

NASDAQ:REPL opened at $8.78 on Wednesday. The company has a market capitalization of $724.96 million, a price-to-earnings ratio of -2.55 and a beta of 0.91. Replimune Group, Inc. has a one year low of $1.50 and a one year high of $13.24. The stock has a 50-day simple moving average of $5.27 and a 200 day simple moving average of $7.25. The company has a debt-to-equity ratio of 0.33, a quick ratio of 5.60 and a current ratio of 5.60.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.